the hesitation in the decision not to recommend. what was the thinking behind overcoming that concern in the netherlands? so first... the vaccine that has been recommended and that has been given here in the netherlands is a vaccination programme for 12—18—year—olds, which started in the first week ofjuly. uptake is very high and the consideration was one, it is important first of all to look at the risk—benefit for the children themselves. and then obviously the vaccines have been linked in rare cases, one in 10,000, one on 100,000, with incidences like myocarditis, but we should realise that the same associations have been made with covid itself, so... what may be associated with the vaccine is also associated with the virus itself, that is one important thing. and the same pertains to rare instances of systemic inflammation with children. now, the other important issue and the first discussion